Showing results (41-50 of 110) with videos related to
Sort By:
Pageof 11
Leukemia & Lymphoma|July 16, 2010
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conferenceMartin Dreyling, Eva Hoster, Silvia Bea, et al.Haematologica|June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma AllianceChristian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2005
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)Georg Lenz, Martin Dreyling, Eva Hoster, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcomeAnnika Dufour, Friederike Schneider, Klaus H Metzeler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Improvement of overall survival in advanced stage mantle cell lymphomaAnnina Herrmann, Eva Hoster, Thomas Zwingers, et al.Haematologica|May 13, 2014
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapseMax Hubmann, Thomas Köhnke, Eva Hoster, et al.Annals of Hematology|February 25, 2012
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patientsAnnika Dufour, Friederike Schneider, Eva Hoster, et al.Annals of Hematology|August 8, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysisLuca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, et al.Leukemia|September 16, 2024
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trialsMouhamad Khouja, Linmiao Jiang, Karol Pal, et al.Blood|May 30, 2015
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie-Hélène Delfau-Larue, Wolfram Klapper, Françoise Berger, et al.Pageof 11